Neurocrine wraps $235M diabetes pact with Boehringer; Arginetix merges with Immune Control, raises $15M;

 @FierceBiotech: Cipla targets $19B biosimilar market with string of new deals. Report | Follow @FierceBiotech

 @JohnCFierce: Here's New York Times' piece on FDA's thoughts on Boehringer's libido drug. Looks like another cruel panel flogging is coming. Report | Follow @JohnCFierce

> Just a day after announcing a $575 million development pact with Abbott, Neurocrine Biosciences wrapped a somewhat smaller pact with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for Type II diabetes and other indications. Neurocrine gets $10 million upfront and up to $225 million in milestones. Neurocrine release

> Arginetix and Immune Control are merging under the name of Corridor Pharmaceuticals, which will explore new vascular disease therapies. Corridor also landed $15 million in financing to get its lead drug into the clinic. Story

> An FDA panel will meet at the end of January to review Orexigen's obesity drug Contrave, one of several new weight drugs now up for approval. Report

> Xoma saw its badly battered shares jump on the news that a small trial of its uveitis therapy produced promising results. Story

> Teva is exercising its option to invest in Israel's Andromeda Biotech. Teva and Clal Biotechnology Industries will invest an additional total of $17.5 million in Andromeda. Teva release

> European regulators provided Allos Therapeutics with orphan drug status for its cutaneous T-cell lymphoma drug. Report

> Charles River shareholder Neuberger Berman is joining the growing opposition to the $1.6 billion acquisition of WuXi. The Charles River CEO, though, insists that he has the support needed to see the buyout through. Story

And Finally... An international clinical trial led by researchers at the Harvard School of Public Health found that AIDS-fighting antiretroviral drug combinations given to pregnant and breastfeeding women in Botswana prevented 99 percent of the mothers from transmitting the human immunodeficiency virus to their infants. Report

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.